FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016794123> ?p ?o ?g. }

• W2016794123 endingPage "1223" @default.
• W2016794123 startingPage "1218" @default.
• W2016794123 abstract "Background Resistance to the affordable malaria treatments chloroquine and pyrimethamine-sulfadoxine is seriously impeding malaria control through treatment in east Africa. We did an open, alternate drug allocation study to assess the efficacy of chlorproguanil-dapsone in the treatment of falciparum malaria clinically resistant to pyrimethamine-sulfadoxine. Methods Children younger than 5 years with non-severe falciparum malaria, attending Muheza district hospital in Tanzania, were treated with the standard regimen of pyrimethamine-sulfadoxine. Patients whose clinical symptoms resolved but who remained parasitaemic 7 days after pyrimethamine-sulfadoxine were followed up for 1 month. Clinical malaria episodes were retreated with either single dose pyrimethamine-sulfadoxine or a 3-day regimen of chlorproguanil-dapsone. Those with parasitaemia after 7 days were treated with chlorproguanil-dapsone. Parasite DNA was collected on day 7 after first treatment with pyrimethamine-sulfadoxine and we looked for point mutations in the genes encoding dihydrofolate reductase (dhfr) and dyhydropteroate synthetase (dhps). Findings 360 children were enrolled and treated with pyrimethamine-sulfadoxine. On day 7, 192 (55%) of 348 had cleared parasitaemia. Of the remaining 156 parasitaemic children, 140 (90%) were followed up to day 28, and 92 (66%) of 140 developed clinical malaria. These 92 patients were alternately retreated with either pyrimethamine-sulfadoxine (46) or chlorproguanil-dapsone (46). 28 (61%) of 46 children retreated with pyrimethamine-sulfadoxine were still parasitaemic at day 7, compared with three (15%) of 46 children retreated with chlorproguanil-dapsone. Resistance to pyrimethamine-sulfadoxine increased from 45% (156/348) at the first treatment to 61% (28/46) after retreatment. 83 of 85 parasite isolates collected after the first pyrimethamine-sulfadoxine treatment, and before and after the second treatments with pyrimethamine-sulfadoxine and chlorproguanil-dapsone showed triple-mutant dhfr alleles, associated with a variety of dhps mutations. Interpretation Most patients treated with pyrimethamine-sulfadoxine, who remain parasitaemic at day 7, develop new malaria symptoms within 1 month. Chlorproguanil-dapsone was a practicable therapy under these circumstances. Analysis of parasite dhfr and dhps before and after treatment supports the view that pyrimethamine-sulfadoxine resistance in this part of Africa is primarily due to parasites with three mutations in the dhfr domain." @default.
• W2016794123 created "2016-06-24" @default.
• W2016794123 creator A5003302916 @default.
• W2016794123 creator A5018692963 @default.
• W2016794123 creator A5022372798 @default.
• W2016794123 creator A5053416884 @default.
• W2016794123 creator A5063330795 @default.
• W2016794123 creator A5069992901 @default.
• W2016794123 creator A5080367708 @default.
• W2016794123 date "2001-10-01" @default.
• W2016794123 modified "2023-09-30" @default.
• W2016794123 title "Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania" @default.
• W2016794123 cites W1982522595 @default.
• W2016794123 cites W1989987500 @default.
• W2016794123 cites W1990887642 @default.
• W2016794123 cites W2002129908 @default.
• W2016794123 cites W2010485888 @default.
• W2016794123 cites W2032150053 @default.
• W2016794123 cites W2034520962 @default.
• W2016794123 cites W2048007395 @default.
• W2016794123 cites W2050341196 @default.
• W2016794123 cites W2052227367 @default.
• W2016794123 cites W2059838568 @default.
• W2016794123 cites W2060793519 @default.
• W2016794123 cites W2061212700 @default.
• W2016794123 cites W2079127050 @default.
• W2016794123 cites W2081635625 @default.
• W2016794123 cites W2089734289 @default.
• W2016794123 cites W2122025531 @default.
• W2016794123 cites W2123470783 @default.
• W2016794123 cites W2124750913 @default.
• W2016794123 cites W2163117814 @default.
• W2016794123 cites W2167296967 @default.
• W2016794123 cites W2168180056 @default.
• W2016794123 cites W2169971066 @default.
• W2016794123 doi "https://doi.org/10.1016/s0140-6736(01)06344-9" @default.
• W2016794123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11675058" @default.
• W2016794123 hasPublicationYear "2001" @default.
• W2016794123 type Work @default.
• W2016794123 sameAs 2016794123 @default.
• W2016794123 citedByCount "176" @default.
• W2016794123 countsByYear W20167941232012 @default.
• W2016794123 countsByYear W20167941232013 @default.
• W2016794123 countsByYear W20167941232014 @default.
• W2016794123 countsByYear W20167941232015 @default.
• W2016794123 countsByYear W20167941232016 @default.
• W2016794123 countsByYear W20167941232017 @default.
• W2016794123 countsByYear W20167941232019 @default.
• W2016794123 countsByYear W20167941232020 @default.
• W2016794123 countsByYear W20167941232021 @default.
• W2016794123 countsByYear W20167941232022 @default.
• W2016794123 countsByYear W20167941232023 @default.
• W2016794123 crossrefType "journal-article" @default.
• W2016794123 hasAuthorship W2016794123A5003302916 @default.
• W2016794123 hasAuthorship W2016794123A5018692963 @default.
• W2016794123 hasAuthorship W2016794123A5022372798 @default.
• W2016794123 hasAuthorship W2016794123A5053416884 @default.
• W2016794123 hasAuthorship W2016794123A5063330795 @default.
• W2016794123 hasAuthorship W2016794123A5069992901 @default.
• W2016794123 hasAuthorship W2016794123A5080367708 @default.
• W2016794123 hasConcept C203014093 @default.
• W2016794123 hasConcept C2777035104 @default.
• W2016794123 hasConcept C2777640609 @default.
• W2016794123 hasConcept C2778048844 @default.
• W2016794123 hasConcept C2778301690 @default.
• W2016794123 hasConcept C2778371730 @default.
• W2016794123 hasConcept C2780441369 @default.
• W2016794123 hasConcept C71924100 @default.
• W2016794123 hasConcept C98274493 @default.
• W2016794123 hasConceptScore W2016794123C203014093 @default.
• W2016794123 hasConceptScore W2016794123C2777035104 @default.
• W2016794123 hasConceptScore W2016794123C2777640609 @default.
• W2016794123 hasConceptScore W2016794123C2778048844 @default.
• W2016794123 hasConceptScore W2016794123C2778301690 @default.
• W2016794123 hasConceptScore W2016794123C2778371730 @default.
• W2016794123 hasConceptScore W2016794123C2780441369 @default.
• W2016794123 hasConceptScore W2016794123C71924100 @default.
• W2016794123 hasConceptScore W2016794123C98274493 @default.
• W2016794123 hasIssue "9289" @default.
• W2016794123 hasLocation W20167941231 @default.
• W2016794123 hasLocation W20167941232 @default.
• W2016794123 hasOpenAccess W2016794123 @default.
• W2016794123 hasPrimaryLocation W20167941231 @default.
• W2016794123 hasRelatedWork W1746729210 @default.
• W2016794123 hasRelatedWork W1903390813 @default.
• W2016794123 hasRelatedWork W1968032611 @default.
• W2016794123 hasRelatedWork W1984383715 @default.
• W2016794123 hasRelatedWork W2013263702 @default.
• W2016794123 hasRelatedWork W2022025781 @default.
• W2016794123 hasRelatedWork W2410936441 @default.
• W2016794123 hasRelatedWork W2429268174 @default.
• W2016794123 hasRelatedWork W2436584172 @default.
• W2016794123 hasRelatedWork W2437441723 @default.
• W2016794123 hasVolume "358" @default.
• W2016794123 isParatext "false" @default.
• W2016794123 isRetracted "false" @default.
• W2016794123 magId "2016794123" @default.
• W2016794123 workType "article" @default.